The companies said they will closely collaborate on formulation, optimization and in vitro testing. Under the terms of the pact, BioNTech will provide an unspecified upfront access fee to work exclusively with the New Jersey-based firm, as well as additional research funding.
The two said they have also begun discussing a license agreement for Matinas' lipid nanocrystal platform technology.
Shares of Matinas BioPharma were up more than 9% in recent premarket trading, while shares of BioNTech were down nearly 2%.
Price: 167.44, Change: -2.82, Percent Change: -1.66
|-- Earnings Flash (ANY) SPHERE 3D Posts Q2 Revenue $...|
|-- Earnings Flash (AWX) AVALON HOLDINGS CORPORATION ...|
|-- Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Repo...|
|Research Alert: CFRA Retains Hold Opinion On Shares ...|
|US Stocks Climb as Inflation Expectations Wane|